NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated August 1, 2026

Supplement × Prescription·Evidence index

Calcium and Pantoprazole: what the published research says

PubMed indexes 6 records that name Calcium and Pantoprazole together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.

Read this first

An evidence index, not guidance.

Every statement below is attributed to a named, dated, linked source.

This page lists published research relevant to Calcium and Pantoprazole. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.

The research

6 studies naming Calcium and Pantoprazole.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.

Clinical drug investigation · 2014 · PMID 24935051

Randomized Controlled Trial

“The pharmacokinetic parameters of cinacalcet were not affected by co-administration of CaCO(3), sevelamer HCl or pantoprazole. Co-administration of these agents with cinacalcet does not require an adjustment of the dose of cinacalcet.”

Padhi et al. · Authors' conclusion

Names both Calcium and Pantoprazole in its title.

Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.

Nephrology (Carlton, Vic.) · 2012 · PMID 22471559

Randomized Controlled Trial26 participants

“These results demonstrate clinical evidence for an adverse effect of gastric acid suppression on the effectiveness of calcium carbonate phosphate binders. Given their frequent co-prescription, this interaction may be a minor but common reason why some patients fail to control hyperphosphataemia. Clinicians should regularly assess the need for acid suppressants. Further studies are needed to investigate interactions with other phosphate binders.”

Cervelli et al. · Authors' conclusion

Names both Calcium and Pantoprazole in its title.

Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.

European journal of clinical pharmacology · 2022 · PMID 34714373

Observational StudyHuman subjects

“The study findings proved a negative impact of pantoprazole use on Ca2+ and Mg2+ levels, which can impact TRPM7-mediated bone remodelling which serves to be a possible mechanism for osteoporosis upon pantoprazole use.”

Desai et al. · Authors' conclusion

Names Calcium and Pantoprazole together in an interaction, co-administration, or pharmacokinetic context.

A case series of proton pump inhibitor-induced hypomagnesemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation · 2010 · PMID 20189276

Case ReportsHuman subjects

Names Calcium and Pantoprazole together in an interaction, co-administration, or pharmacokinetic context.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Calcium, Pantoprazole, and several hundred other substances.

The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.